Healthcare Contract Manufacturing Market | Trending Key Players - Patheon (Netherlands), Lonza (Switzerland), Evonik Industries (Germany), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim BioXcellence (Germany), Famar S.A. (Greece), Fareva Gr

Global healthcare contract manufacturings consist of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas holds the largest share of the global healthcare contract manufacturing market owing to the rising number of drug approvals as one of the factors fuelling the growth. The patent expiries of blockbuster drugs are creating a new opportunity to vendors to develop biosimilars at low cost. Thus, the market is anticipated entry of biosimilars and generics, which is likely to further strengthen the growth in this region.

The European market dominated the global healthcare contract manufacturings market owing to the high prevalence rate of various disease in the Eastern European regions.

The Asia Pacific region is anticipated to be the fastest growing region over the forecast period owing to the increasingly favorable government initiatives along with the improving healthcare infrastructure.

Get a sample report at https://www.marketresearchfuture.com/sample_request/5637 .

Healthcare contract manufacturing refers to pharmaceutical and biotechnological companies outsourcing the manufacturing of raw materials or drugs to contract manufacturing organizations (CMO). These CMOs delivers the manufacturing services for finished dosage formulations as well as active pharmaceutical ingredients. In June 2017, Recipharm, a CMO, and Kancera, a development company focused on cancer therapy mutually agreed to sign a contract for the development and manufacture of the pharmaceutical candidate, KAND567.

The rising number manufacturing facilities, which are of FDA approved in emerging countries are responsible for the market growth over the coming years. For instance, India comprises of over 100 manufacturing facilities which are FDA approved as it is the most favorable locations for outsourcing manufacturing services.

The factors such as drug shortage leading to increasing demand for pharmaceutical development, the commercial success of biologics for clinical use, lower manufacturing costs, and improving economic condition of BRIC are driving the market growth over the forecast period. In addition, limited outsourcing among big pharma companies clients along with the regulatory issues pertaining to the drug approval are some of the factors restraining the market from growing.

The global market for healthcare contract manufacturing is expected to grow at a CAGR of approximately 6.5% during the forecast period 2017-2023.

More inquire at https://www.marketresearchfuture.com/enquiry/5637 .

Key Players

Some of key the players in the global healthcare contract manufacturings market are Patheon (Netherlands), Lonza (Switzerland), Evonik Industries (Germany), Teva Pharmaceutical Industries (Israel), Boehringer Ingelheim BioXcellence (Germany), Famar S.A. (Greece), Fareva Group (France), Vetter Pharma International (Germany), Mylan (U.S.), Recipharm (Sweden), Aesica Pharmaceuticals (U.K.), Althea Technologies (U.S.), Aenova (Germany), Dishman Pharmaceuticals and Chemicals Limited (India), Catalent Pharma Solutions (U.S.), Kemwell Pvt. Ltd. (India), Jubilant Life Sciences Limited (India), Nipro Corporation (Japan), NextPharma (UK), Pfizer Central Source (U.S.), Royal DSM N.V. (Netherlands), Abbott Laboratories (U.S.), Amgen (U.S.), Apotex (U.S.), Aspen (U.S.), AstraZeneca PLC (UK), Aurobindo Pharma (India), Baxter International (U.S.), BERLIN-CHEMIE (Germany), Biocon (India), Biogen (U.S.), Celltrion (South Korea), Cipla (India), Coherus Biosciences (U.S.), Daiichi Sankyo (Japan), Dr. Reddy's Laboratories (India), Eli Lilly and Company (U.S.), Emcure Pharmaceuticals (India), Eurofarma Laboratories (Brazil), Gedeon Richter (Hungary), Gilead Sciences (U.S.), GlaxoSmithKline (GSK) Plc (U.S.), Hospira (U.S.), Impax Laboratories (U.S.), Intas Pharmaceuticals (India), Janssen Pharmaceuticals (U.S.), Lupin (India), Merck and Co. Inc. (U.S.), Mitsubishi Tanabe Pharma (Japan), Momenta Pharmaceuticals (U.S.), Natco Pharma (India), Nexus Pharmaceuticals (U.S.), Novo Nordisk (Denmark), Orchid Chemicals & Pharmaceuticals (India), Par Pharmaceutical (U.S.), Parenteral Drugs (India), Piramal (India), Roche Holding (Switerzland), Sanofi (France), Synthon (Netherlands), Teva Pharmaceuticals (Israel), Valeant Pharmaceuticals (Canada), Zentiva (Czech Republic), Zhejiang Huahai Pharmaceutical (China), Zydus Cadila (India), and others.

Segmentation

The global healthcare contract manufacturing market is segmented on the basis of product, industry, type, and services.

On the basis of the product, the global healthcare contract manufacturing market is segmented into active pharmaceutical ingredients (API), final dosage formulations (FDF), advanced drug delivery products, OTC medicines and nutritional products, and others. Moreover, the finished dosage formulations (FDF) is segmented into a tablet, capsules, oral liquids, parenteral/injectables, and others.

On the basis of the industry, the global healthcare contract manufacturing market is segmented into pharmaceutical, biopharmaceutical, and others.

On the basis of the type, the global healthcare contract manufacturing market is segmented into sterile, non-sterile, and others

On the basis of the service, the global healthcare contract manufacturing market is segmented into oncology research, vaccines research, inflammation & immunology research, cardiology research, neuroscience research, and others.

About us
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
P: +1 646 845 9312
W: www.marketresearchfuture.com
sales@marketresearchfuture.com

This release was published on openPR.